Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 11/20 | 0.88 |
| ▸ | SRC | P12931 | 8/20 | 0.88 |
| ▸ | LCK | P06239 | 4/20 | 0.88 |
| ▸ | PKMYT1 | Q99640 | 3/20 | 0.88 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.88 |
| ▸ | EGFR | P00533 | 2/20 | 0.88 |
| ▸ | FYN | P06241 | 2/20 | 0.88 |
| ▸ | CSF1R | P07333 | 2/20 | 0.88 |
| ▸ | YES1 | P07947 | 2/20 | 0.88 |
| ▸ | LYN | P07948 | 2/20 | 0.88 |
| ▸ | RET | P07949 | 2/20 | 0.88 |
| ▸ | HCK | P08631 | 2/20 | 0.88 |
| ▸ | KIT | P10721 | 2/20 | 0.88 |
| ▸ | BCR | P11274 | 2/20 | 0.88 |
| ▸ | BRAF | P15056 | 2/20 | 0.88 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.88 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.88 |
| ▸ | EPHA3 | P29320 | 2/20 | 0.88 |
| ▸ | EPHA8 | P29322 | 2/20 | 0.88 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29618210 | 1.00 | ABL1 (0.88) | ABL1SRCLCKPKMYT1EPHB6 | |
| SCHEMBL28935340 | 0.96 | ABL1 (0.87) | ABL1SRCLCKPKMYT1EPHB6 | |
| SCHEMBL29618215 | 0.96 | ABL1 (0.87) | ABL1SRCLCKPKMYT1EPHB6 | |
| SCHEMBL13164781 | 0.94 | ABL1 (0.88) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL8226 | 0.94 | ABL1 (1.00) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL29381185 | 0.94 | ABL1 (1.00) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL28350326 | 0.94 | ABL1 (1.00) | ABL1SRCLCKPKMYT1EPHB6 | |
| SCHEMBL31501075 | 0.93 | ABL1 (0.89) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL16618598 | 0.93 | ABL1 (1.00) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL20857008 | 0.93 | ABL1 (0.98) | ABL1SRCLCKPKMYT1EPHB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250064837-A1 | TARGET PROTEIN DEGRADATION COMPOUNDS, THEIR ANTI-TUMOR USE, THEIR INTERMEDIATES AND USE OF INTERMEDIATES | SHANGHAITECH UNIVERSITY (CN) | 2025-02-27 | — | — | US | disclosed |
| US-12226424-B2 | Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates | SHANGHAITECH UNIVERSITY (CN) | 2025-02-18 | — | — | US | disclosed |
| US-20220117982-A1 | TARGET PROTEIN DEGRADATION COMPOUNDS, THEIR ANTI-TUMOR USE, THEIR INTERMEDIATES AND USE OF INTERMEDIATES | SHANGHAITECH UNIVERSITY (CN) | 2022-04-21 | — | — | US | disclosed |
| CN-110357889-B | Protein degradation targeting compound, anti-tumor application thereof, intermediate thereof and application of intermediate | 上海科技大学 | 2022-03-15 | — | — | CN | disclosed |
| EP-3778590-A1 | PROTEIN DEGRADATION TARGETING COMPOUND, ANTI-TUMOR APPLICATION, INTERMEDIATE THEREOF AND USE OF INTERMEDIATE | ShanghaiTech University (CN) | 2021-02-17 | — | — | EP | disclosed |
| US-20100226853-A1 | Fluorine-18 derivatives of dasatinib and uses thereof | UNITED STATES DEPARTMENT OF ENERGY | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250064837-A1 | TARGET PROTEIN DEGRADATION COMPOUNDS, THEIR ANTI-TUMOR USE, THEIR INTERMEDIATES AND USE OF INTERMEDIATES | UFM1, SUMO1, SUMO2 | ABL1 3044/4885SRC 1668/4885LCK 3673/4885 |
| US-12226424-B2 | Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates | UFM1, SUMO1, SUMO2 | ABL1 3132/4885SRC 1824/4885LCK 3730/4885 |
| US-20100226853-A1 | Fluorine-18 derivatives of dasatinib and uses thereof | CHEK1, CDC42BPA, PAK3 | ABL1 36/4885SRC 224/4885LCK 1341/4885 |
| US-20220117982-A1 | TARGET PROTEIN DEGRADATION COMPOUNDS, THEIR ANTI-TUMOR USE, THEIR INTERMEDIATES AND USE OF INTERMEDIATES | UFM1, SUMO1, SUMO2 | ABL1 3132/4885SRC 1824/4885LCK 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.